Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma
Phase of Trial: Phase II
Latest Information Update: 05 Apr 2019
Price : $35 *
At a glance
- Drugs Monoclonal antibody 3F8 (Primary) ; Granulocyte macrophage colony stimulating factor; Isotretinoin
- Indications Neuroblastoma
- Focus Therapeutic Use
- 02 Apr 2019 Status changed from recruiting to completed.
- 08 Feb 2019 Planned End Date changed from 1 Mar 2019 to 1 Mar 2020.
- 08 Feb 2019 Planned primary completion date changed from 1 Mar 2019 to 1 Mar 2020.